Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADOT - BIOMODA: Profitable Technology with Purpose -- Ignore unavailable to you. Want to Upgrade?

To: Elio Madama who wrote (2574)	1/30/1999 2:05:00 PM
From: Elio Madama	Read Replies (1) \| Respond to of 4650

***********MORE FROM 1998*********** ====================================================================== PR NEWSWIRE) DJ: Biomoda, Inc. Receives Offer to Take Company Public; Mov DJ: Biomoda, Inc. Receives Offer to Take Company Public; Move Would Have Positive Impact on Advanced Optics Electronics ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Sept. 9, 1998--Advanced Optics Electronics, Inc. (OTC BB: ADOT) today announced that Biomoda, Inc. has notified Advanced Optics that Biomoda has received a preliminary offer from an investment banking firm to take Biomoda, Inc. public. The Company will release specifics of this proposed public offering of Biomoda shares as negotiations progress. Advanced Optics Electronics owns approximately 22% of Biomoda, Inc., with an option to increase its holdings to 27%. Biomoda, Inc. owns a patented lung cancer test capable of detecting lung cancer up to six years earlier than any other available test. A final double-blind study of the effectiveness of Biomoda's revolutionary non-invasive test is currently being conducted by LungCheck(R), Inc. of Scottsdale, Ariz., with results expected to be completed by the end of September. These results will be sent for confirmation to a prestigious institution on the East coast, with further confirmation expected by the first week in October. Verified results will be submitted to various medical journals for publication as well as to the national media. Biomoda's technology also encompasses the treatment of lung cancer. Biomoda's prominent research team has included world-leading cytopathologists, Dr. Geno Saccomanno of St. Mary's Hospital and Medical Center, Dr. Jim Mulshine of the National Cancer Institute and the late Dr. John Frost of Johns Hopkins University. Also currently involved in Biomoda's research is Dr. L. Edward Ellinwood, a nationally recognized pharmacologist from St. Mary's Hospital and Los Alamos National Laboratories. Biomoda believes this technology is a leading hope for a cure for lung cancer. FDA approval will not be necessary for the patented non-invasive lung cancer test, but will be required for the patented treatment process. Biomoda, Inc. is currently in discussions with several major pharmaceutical companies regarding this patented technology. It is anticipated that results from this latest round of studies will provide Biomoda with the data necessary to conclude major marketing and distribution agreements with several major partners in the United States and abroad. This press release contains forward-looking statements with respect to the results of operations, expectations and business of the Company that involves risk and uncertainties. The Company's actual future results could materially differ from those discussed. Risks and uncertainties of the Company will be detailed from time to time in the Company's periodic reports to be filed with the Securities and Exchange Commission. ADVANCED OPTICS COMPANY INFORMATION ADOT owns approximately 22% of Biomoda, Inc., an emerging biomedical company specializing in breakthrough cancer diagnostics and therapy. Advanced Optics Electronics, Inc. (OTC Bulletin Board: ADOT - news) is a developer of patented electronic display technology, utilizing ADOT's proprietary SLM (Spatial Light Modulator) light valve. This industry-leading technology can be utilized in many diverse fields including the production of "television quality" advertising billboards, medical testing equipment, military displays, computer monitors and high definition video transmission. Advanced Optics Electronics actively seeks partnerships with companies in fields that could benefit from ADOT's patented technology. CONTACT: Advanced Optics Electronics, Inc. (505) 797-7878 Web site: adot.org. 14:07 EDT SEPTEMBER 9, 1998

To: Elio Madama who wrote (2574)	1/30/1999 2:07:00 PM
From: Elio Madama	Respond to of 4650

*****JUST FEW MORE PAST PR******** ===================================================================== (BSNS WIRE) Advanced Optics Electronics Inc. Increases BioModa Holding Advanced Optics Electronics Inc. Increases BioModa Holding Business Editors ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Oct. 26, 1998--Advanced Optics Electronics Inc. (OTC BB:ADOT) announced that it has begun to exercise part of its option to increase its position in BioModa Inc. By exercising this part of its option, Advanced Optics Electronics Inc. holdings in BioModa increased from 21.5 percent to 22.8 percent. Advanced Optics Electronics Inc. option if fully exercised allows Advanced Optics Electronics Inc. position to move to approximately 26.5 percent of BioModa Inc. BioModa Inc. has patents covering its worldwide, exclusively licensed technology and have been issued in Australia, Korea and the Russian Federation. Additional patents are pending in Europe, Asia and South America. This news release contains forward-looking statements with respect to the results of operations and business of the company that involves risk and uncertainties. The company's actual future results could materially differ from those discussed. Risks and uncertainties of the company will be detailed from time to time in the company's periodic reports to be filed with the Securities and Exchange Commission. Contact Advanced Optics Electronics Inc. at 505/797-7878 or visit their web site at adot.org. --30--kjs/ix* sig/ix CONTACT: Advanced Optics Electronics Inc., Albuquerque 505/797-7878 www.adot.org KEYWORD: NEW MEXICO INDUSTRY KEYWORD: COMPUTERS/ELECTRONICS COMED MEDICINE Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com

To: Elio Madama who wrote (2574)	1/30/1999 2:16:00 PM
From: Elio Madama	Respond to of 4650

***********ANOTHER PRESS RELEASE********** =====================================================================(BSNS WIRE) Advanced Optics Electronics Inc. Announces: BioModa Inc. ''H Advanced Optics Electronics Inc. Announces: BioModa Inc. ''Human Clinical Testing Shows Value of New Diagnostic for Early Detection of Lung Cancer'' Business Editors ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Nov. 16, 1998--BioModa Inc. Monday announced the successful completion of the first commercial clinical testing of its TCPP lung cancer diagnostic. An independent, commercial lung cytology laboratory performed the tests. The blinded study has proven that BioModa's technology is now ready to move into the commercialization phase. The company expects to have its test kit in the marketplace by the end of the first quarter of 1999. "This is the validation we've been waiting for. Now it's full speed ahead with the kit," stated Ari Ma'ayan, BioModa's president. BioModa had hoped that the testing would validate the company's conclusion from earlier laboratory work that the technology would be capable of detecting early stages of pre-cancerous conditions of the lung. "The trials have done exactly that," said BioModa's Chief Technical Officer, Jeff Garwin, M.D., Ph.D. "The key to raising the survival rate for any type of cancer is early detection, and up until now there was no test which could accurately, quickly and inexpensively detect patterns of abnormal cells in the lung which could develop into lung cancer. This test should detect those patterns several years before any other diagnostic modality," stated Dr. Garwin. Early detection could raise the 5-year survival rate of lung cancer from 15 percent to 46 percent, and new preventive treatments may be able to halt the progression to lung cancer, if pre-cancerous conditions are detected early enough. Lung cancer strikes nearly 200,000 Americans each year and is the leading cause of cancer death in the United States and the world. BioModa's core technology was developed at Los Alamos National Laboratory and St. Mary's Medical Center in Grand Junction, Colo. BioModa received an exclusive worldwide license to the technology in 1995. The technology is protected by patents, which have issued in the United States and several foreign countries and which are pending in several more. Additionally, the company will file a number of important new patents in the near future. BioModa now intends to start developing products to image and treat lung cancer, based on its exclusive core technology. The company also plans to extend its technology to develop diagnostic tests and treatments for other cancers. Plans call for entering into partnerships with U.S.- and foreign-based corporations for R&D, production, marketing and distribution. Advanced Optics Electronics Inc. currently owns 22.8 percent of BioModa Inc. with an option, if fully exercised which allows Advanced Optics Electronics Inc. position to move to approximately 26.5 percent of BioModa Inc. Advanced Optics Company Information Advanced Optics Electronics Inc. (OTC BB:ADOT news) is a developer of patented electronic display technology, utilizing ADOT's proprietary SLM (Spatial Light Modulator) light valve. This industry-leading technology can be utilized in many diverse fields including the production of "television quality" advertising billboards, medical testing equipment, military displays, computer monitors and high definition video transmission. Shareholder Relations Note ADOT will promptly respond to all requests for information from shareholders and the general public; shareholders will receive priority response. All such requests must be sent to ADOT via FAX: 505/858-1871 or U.S. Mail to 8301 Washington Ave. Building 4, Albuquerque, NM 87113. All such requests must include the name, daytime fax (if available) and street address as box numbers cannot be accepted. This policy is necessitated by the very large number of Internet postings and inquiries, many with pen names which have caused ADOT and other related companies to be overwhelmed with anonymous comments, requests and demands. This news release contains forward-looking statements with respect to the results of operations and business of the company that involves risk and uncertainties. The company's actual future results could materially differ from those discussed. Risks and uncertainties of the company will be detailed from time to time in the company's periodic reports to be filed with the Securities and Exchange Commission. Contact Advanced Optics Electronics Inc. at 505/797-7878 or visit their Web site at www.adot.org. --30--kjs/ix* dlc/ix CONTACT: Advanced Optics Electronics Inc., Albuquerque 505/797-7878 www.adot.org KEYWORD: NEW MEXICO INDUSTRY KEYWORD: COMPUTERS/ELECTRONICS COMED MEDICINE BIOTECHNOLOGY PRODUCT Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com